Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (clinicaltrials.gov) - Oct 2, 2026 - P1 | N=15 | Recruiting | Sponsor: University of Utah | Not yet recruiting ➔ Recruiting
Enrollment open • Tumor mutational burden • Myelofibrosis • CALR • JAK2
|